

Supplementary Table 2 Efficacy outcomes change from baseline to week 12 and 24, for both treatment arms.

Efficacy outcomes	Median change GLM+MTX	Median change PLB+MTX	P value	Median change GLM+MTX	Median change PLB+MTX	P value
Peripheral joints						
Tender joints (DAS28)	-3.0	-1.0	0.218	-2.5	-2.5	0.507
Swollen joints (DAS28)	-2.5	-1.0	0.379	-2	-2	0.523
Patient- and physician-reported outcomes						
PGA for arthritis and psoriasis activity (0-100mm)	-22.5	-15.0	0.367	-28	-12.5	0.174
PGA for pain (0-100mm)	-26.5	-19	0.223	-34	-17.5	0.278
PGA for axial activity (0-100mm) *	-13.5	-8.5	0.577	-1	-13	0.917
PhGA for arthritis and psoriasis activity (0-100mm)	-20	-10	0.103	-35	-22.5	0.261
PhGA for axial activity (0-100mm) *	-5	0	0.062	-5	0	0.375
PhGA for arthritis activity (0-100mm)	-20	-20	0.248	-30	-20	0.153
PhGA for psoriasis activity (0-100mm)	-12	-10	0.084	-27.5	-18.5	0.153
BASDAI*	-2.45	-1.7	0.131	-3.8	-1.6	0.177
Physical function						
BASFI*	-0.78	-0.06	0.074	-0.79	-0.83	0.330
Laboratory inflammatory markers						
Erythrocyte sedimentation rate (mm/1 st h)	-14.5	-5	0.137	-12	-3.5	0.224
C reactive protein (mg/L)	-4.2	-3.1	0.495	-5.1	-3.9	0.676
Composite indices of disease activity						
CDAI	-9.55	-5.6	0.064	-10.5	-8.3	0.162
CDAI remission	3/20 (15)	0/23 (0)	0.092	8/20 (40)	2/22 (9.0)	0.030
SDAI	-10.06	-5.57	0.062	-11.67	-9.59	0.134
SDAI remission	4/16 (25)	0/23 (0)	0.039	9/19 (47.4)	3/22 (13.6)	0.037
ASDAS ESR	-1.55	-0.8	0.014	-1.8	-0.6	0.065
Response indices						
ASDAS response*	No response, n (%)	5/12 (41.7)	8/16 (50)		5/11 (45.5)	10/15 (66.7)
	Clinically important (≥ 1.1), n (%)	4/12 (33.3)	6/16 (37.5)	0.775	2/11 (18.1)	2/15 (13.3)
	Major improvement (≥ 2), n (%)	3/12 (25.0)	2/16 (12.5)		4/11 (36.1)	3/15 (20.0)
ASAS response*	ASAS 20, n (%)	0	0	NA	0	0
	ASAS 40, n (%)	0	0	NA	0	0
	ASAS 70, n (%)	0	0	NA	0	0

ASAS: Assessment in Spondyloarthritis International Society; ASDAS ESR: Ankylosing Spondylitis Disease Activity Erythrocyte sedimentation rate; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; CDAI: Clinical Disease Activity Index; DAS28 4v: Disease Activity Score 4 variables; GLM: golimumab; MTX: methotrexate; n: number; NA: not applicable; PASI: Psoriasis Area and Severity Index; PGA: patient global assessment; PhGA: physician global assessment; PLB: placebo; SDAI: Simple Disease Activity Index. *only for those with axial involvement